Adagene Inc. Files 2024 Annual Report

Ticker: ADAG · Form: 20-F · Filed: Mar 24, 2025 · CIK: 1818838

Adagene INC. 20-F Filing Summary
FieldDetail
CompanyAdagene INC. (ADAG)
Form Type20-F
Filed DateMar 24, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: annual-report, 20-F, pharmaceuticals

TL;DR

Adagene dropped its 2024 20-F. Check financials.

AI Summary

Adagene Inc. filed its annual report on Form 20-F for the fiscal year ending December 31, 2024. The company, incorporated in E9 and headquartered in Suzhou Industrial Park, Jiangsu, operates in the Pharmaceutical Preparations sector. The filing details its financial performance and business operations for the reporting period.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of Adagene Inc.'s financial health and strategic direction for the past fiscal year, crucial for investment decisions.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Adagene faces inherent risks related to drug development, regulatory approvals, and market competition, which are detailed in its 20-F filing.

Key Numbers

Key Players & Entities

FAQ

What is Adagene Inc.'s primary business sector?

Adagene Inc. operates in the Pharmaceutical Preparations sector, as indicated by its SIC code [2834].

When did Adagene Inc. file its 20-F report?

Adagene Inc. filed its 20-F report on March 24, 2025.

What is the fiscal year end for Adagene Inc. in this filing?

The fiscal year end for Adagene Inc. in this filing is December 31, 2024.

Where is Adagene Inc. located?

Adagene Inc.'s business and mailing address is located at 4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park, Jiangsu.

What is the SEC file number for Adagene Inc.'s filing?

The SEC file number for Adagene Inc.'s filing is 001-39997.

Filing Details

This Form 20-F (Form 20-F) was filed with the SEC on March 24, 2025 regarding Adagene Inc. (ADAG).

View full filing on EDGAR

View Full Filing

View this 20-F filing on SEC EDGAR

View on Read The Filing